Lokomat exoskeleton versus C‑Mill treadmill for improving walking after stroke
Comparative Study of Working With the LoKomat® Exoskeleton VS C-Mill® Treadmill for Gait Recovery in Rehabilitation and Improvement of Quality of Life in Adult Stroke Patients. Randomised Clinical Trial.
This trial will test whether Lokomat exoskeleton therapy or C‑Mill treadmill training helps adults after stroke walk better and feel better in daily life.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 40 (estimated) |
| Ages | 18 Years to 65 Years |
| Sex | All |
| Sponsor | Universidad Pontificia de Salamanca Academic / other |
| Locations | 1 site (Salamanca) |
| Trial ID | NCT07230470 on ClinicalTrials.gov |
What this trial studies
This single‑center comparison enrolls adults with ischemic or hemorrhagic stroke who can consent and are eligible for robotic gait therapy. Participants receive a course of gait rehabilitation using either the Lokomat exoskeleton or the C‑Mill treadmill and are monitored in the neurorehabilitation clinic. Outcomes include objective gait measures (speed, balance), spasticity, and patient-reported quality of life measured before and after the intervention. Patients with major cognitive deficits, other neurologic disorders, or musculoskeletal problems that prevent safe device use are excluded.
Who should consider this trial
Good fit: Adults with a confirmed diagnosis of stroke who are cognitively able to give informed consent and have no contraindications to the robotic devices are ideal candidates.
Not a fit: Patients with severe cognitive impairment, other concomitant neurological diseases, disabling arthritis or osteoarthritis, or specific contraindications to the devices are unlikely to benefit from participation.
Why it matters
Potential benefit: If successful, the intervention could help patients regain walking ability, reduce spasticity, and improve daily functioning and quality of life.
How similar studies have performed: Previous studies of both Lokomat and C‑Mill have shown improvements in gait speed, balance, and functional recovery in stroke patients, though direct comparative data are limited.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Diagnosis of stroke (haemorrhagic and/or ischaemic) by a specialist physician. . * Subjects who are cognitively capable and who sign the informed consent form. Exclusion Criteria: * Severe cognitive impairment (Mini-Mental State Examination \< 24.), or impairment that prevents correct understanding of the correct understanding of the messages and explanatory orders of the treatment and its conditions. * Diagnosis of concomitant neurological diseases and craniocerebral trauma. cranioencephalic trauma. * Other diseases that interfere with the gait process (e.g. disabling arthritis or arthrosis, other neurological diseases, other neurological diseases). disabling arthritis or osteoarthritis, other concomitant neurological diseases, etc.). \- Contraindications of the robotic tools themselves.
Where this trial is running
Salamanca
- Universidad Pontificia de Salamanca — Salamanca, Spain (Recruiting)
Study contacts
- Study coordinator: Jorge V Velázquez Saornil, PhD.
- Email: jvelazquezsa@upsa.es
- Phone: 655909940
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.